Ironwood Pharma Announces Executive & Director Changes
Ticker: IRWD · Form: 8-K · Filed: Oct 10, 2025 · CIK: 1446847
| Field | Detail |
|---|---|
| Company | Ironwood Pharmaceuticals Inc (IRWD) |
| Form Type | 8-K |
| Filed Date | Oct 10, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance
Related Tickers: IRWD
TL;DR
Ironwood Pharma's board and exec team are shuffling; watch for new strategies.
AI Summary
Ironwood Pharmaceuticals, Inc. announced on October 7, 2025, changes in its executive and director roles. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives. Specific names and dollar amounts related to these changes are not detailed in this initial filing summary.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy, operational focus, or financial outlook.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty regarding future strategy and performance.
Key Players & Entities
- IRONWOOD PHARMACEUTICALS, INC. (company) — Registrant
- October 7, 2025 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
- 100 Summer Street, Suite 2300 (address) — Principal Executive Offices
- Boston, Massachusetts (location) — Principal Executive Offices City and State
- 02110 (zip_code) — Principal Executive Offices Zip Code
FAQ
What specific roles have been affected by the departures and appointments?
The filing indicates departures of certain officers and directors, the election of new directors, and changes to compensatory arrangements for certain officers, but does not specify the exact roles in this summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on October 7, 2025.
What is Ironwood Pharmaceuticals, Inc.'s state of incorporation?
Ironwood Pharmaceuticals, Inc. is incorporated in Delaware.
Where are Ironwood Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 100 Summer Street, Suite 2300, Boston, Massachusetts 02110.
What type of filing is this and what sections of the Securities Exchange Act does it pertain to?
This is a Current Report on Form 8-K, filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 459 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2025-10-10 07:05:31
Key Financial Figures
- $0.001 — ich registered Class A common stock, $0.001 par value IRWD Nasdaq Global Select M
Filing Documents
- tm2528244d1_8k.htm (8-K) — 24KB
- 0001104659-25-098523.txt ( ) — 185KB
- irwd-20251007.xsd (EX-101.SCH) — 3KB
- irwd-20251007_lab.xml (EX-101.LAB) — 33KB
- irwd-20251007_pre.xml (EX-101.PRE) — 22KB
- tm2528244d1_8k_htm.xml (XML) — 4KB
02 Departure of Directors or Certain Officers; Election of
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 7, 2025, Andrew Dreyfus provided notice of his resignation from the Board of Directors of Ironwood Pharmaceuticals, Inc. (the "Company"), effective November 1, 2025. Mr. Dreyfus' decision to resign is due to his appointment as President and Chief Executive Officer of the National Institute for Health Care Management (NIHCM) Foundation and was not a result of any disagreement with the Company or any matter relating to the Company's operations, policies or practices. The Company thanks Mr. Dreyfus for his service and the many contributions he made to the Company during his tenure on the Board of Directors. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Ironwood Pharmaceuticals, Inc. Dated: October 10, 2025 By: /s/ Gregory Martini Name: Gregory Martini Title: Senior Vice President, Chief Financial Officer